NCT06265545
- Conditions
- AML, Disease Attributes, Pathologic Processes, +4 more
- Locations
-
- Blood Hospital Tianjin, China
Clinical trial condition
Refractory
Explore clinical trials studying Refractory. Study availability and eligibility vary by location and protocol.
17 public trials
9 recruiting studies
Refractory trial results
NCT06090864
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +13 more
- Locations
-
- Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
NCT07424092
- Conditions
- Disease Attributes, Embryonal Tumor of Brain, Ependymoma, +15 more
- Locations
-
- Princess Máxima Centrum Utrecht, Netherlands
- Cancer Center Clínica Universidad de Navarra Pamplona, Navarre, Spain
Recruiting
xDRIVE for Florida-based Cancer Patients
NCT07167381
- Conditions
- Cancer, Disease Attributes, Hematologic Diseases, +17 more
- Locations
-
- First Ascent Biomedical Miami, Florida, United States
- Florida International University Miami, Florida, United States
NCT06892145
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Immune System Diseases, +4 more
- Locations
-
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Hefei, Anhui, China
- The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China
NCT07295704
- Conditions
- Center-involved Diabetic Macular Edema, Initial, Micropulse Laser, +2 more
- Locations
-
- the General Authority for Teaching Hospitals and Institutes Cairo, Egypt
NCT06622694
- Conditions
- Anemia, Anemia, Aplastic, Bone Marrow Diseases, +11 more
- Locations
-
- Regenerative Medicine Clinic Center Tianjin, Tianjin Municipality, China
NCT06424301
- Conditions
- Eye Diseases, Eye Diseases, Hereditary, Eye Neoplasms, +12 more
- Locations
-
- Fudan Eye & ENT Hospital Shanghai, China
Recruiting
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
NCT06732232
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
- Locations
-
- China, Shanghai Mengchao Cancer Hospital Shanghai, China
Not yet recruiting
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma
NCT07686744
- Conditions
- Adenocarcinoma, Advanced, Carcinoma, +21 more
- Locations
-
- Peking University First Hospital Beijing, Beijing Municipality, China